Hillstream BioPharma, Inc. (HILS): history, ownership, mission, how it works & makes money

From its founding in 2019 to its public debut and strategic pivots, Hillstream BioPharma-now Tharimmune, Inc. (Nasdaq: THAR)-has built a focused biotech story: after acquiring NanoProteagen in September 2019 and the proprietary QUATRAMER delivery platform (and lead compounds like HSB‑114), the company raised $15 million in gross proceeds via an IPO on January 12, 2022 (selling 3,750,000 shares at $4.00 per share), rebranded in September 2023 to emphasize patient-centric clinical development, and in September 2024 struck a definitive licensing agreement with Intract Pharma for an oral anti‑TNF‑alpha monoclonal antibody while planning a merger that would give Intract shareholders 49% of the combined entity (expected to close in Q1 2025); today Tharimmune advances immuno‑oncology assets-leveraging QUATRAMER, bispecific HER2/HER3 antibodies, antibody‑drug conjugates, AI precision‑medicine biomarker platforms, and clinical‑stage additions such as TH104-to commercialize therapies for rare immune, inflammatory and oncologic diseases, monetize through licensing, milestones, partnerships and eventual product sales, and as of December 16, 2025 trades at $2.40 per share with an approximate market capitalization of $3.2 million.

Hillstream BioPharma, Inc. (HILS): Intro

• Founded in 2019 with a focus on developing novel immuno-oncology treatments for rare cancers.
• September 2019: Acquired NanoProteagen, Inc., obtaining the QUATRAMER drug delivery platform and immuno-oncology compounds including HSB-114.
• January 12, 2022: Completed an initial public offering of 3,750,000 shares at $4.00 per share, raising $15.0 million.
• September 2023: Rebranded to Tharimmune, Inc. to reflect a strategic shift toward patient-focused clinical development.
• September 2024: Entered a definitive licensing agreement with Intract Pharma for an oral anti-TNF-alpha monoclonal antibody aimed at improving patient compliance.
• As of December 16, 2025: Tharimmune (ticker THAR) trading at $2.40 per share with an approximate market capitalization of $3.2 million.

• Public company (IPO 2022) with shares originally issued at $4.00; free float reduced as market cap contracted to ~ $3.2M by 12/16/2025.
• Share count implied by market cap and price: ~1.33 million shares outstanding (market cap $3.2M / $2.40 per share ≈ 1,333,333 shares).
• Key institutional/insider holdings: typical small-cap biotech profile-founders, early investors, and venture stakeholders retained meaningful positions post-IPO (specific % holdings vary and require latest SEC filings for exact figures).

• Develop first-in-class and best-in-class immuno-oncology therapies for rare and underserved cancers.
• Advance patient-focused modalities (including oral biologics) to improve adherence and quality of life.
• Leverage proprietary delivery platforms (QUATRAMER) and partnered assets to accelerate clinical translation.

• QUATRAMER drug delivery platform: engineered to enhance tumor targeting and immune activation for payloads including peptides and biologics.
• Lead immuno-oncology assets (e.g., HSB-114): designed to modulate tumoral immune microenvironments in rare cancer indications.
• Licensed oral anti-TNF-alpha monoclonal antibody (via Intract Pharma deal): intended to enable oral delivery of biologic therapy to improve patient compliance versus injectable formats.

• IPO proceeds: $15.0M (January 12, 2022).
• Share price (12/16/2025): $2.40; implied market cap ≈ $3.2M.
• Implied diluted share count: ≈1.33M shares outstanding (market cap / price).
• R&D focus: clinical-stage immuno-oncology programs + licensed oral biologic platform.

Hillstream BioPharma, Inc. (HILS): History

• Founded as a clinical-stage biotech with emphasis on biologics and novel therapeutic platforms.
• Completed multiple preclinical-to-clinical transitions for lead candidates.
• Pursued strategic partnerships and mergers to accelerate commercialization and diversify assets.

• Tharimmune, Inc. is a publicly traded company listed on The Nasdaq Capital Market under the ticker symbol 'THAR.'
• The company has a diverse shareholder base, including institutional investors, individual shareholders, and company insiders.
• In September 2024, Tharimmune entered into a definitive agreement with Intract Pharma, with Intract's shareholders set to own 49% of the combined entity post-merger.
• The merger with Intract Pharma is expected to close in the first quarter of 2025, subject to customary closing conditions.
• Following the merger, the combined entity will continue to trade on The Nasdaq Capital Market under the ticker symbol 'THAR.'
• The merger aims to strengthen Tharimmune's position in the biologics market and expand its therapeutic pipeline.

• R&D and clinical development: investment in discovery and clinical trials for lead biologics and specialty drugs.
• Partnering and licensing: out-licensing candidates or co-development agreements for milestone and royalty revenues.
• Mergers and strategic combinations: accretive transactions (e.g., the Tharimmune-Intract transaction) to broaden pipeline and shareholder base.
• Commercial launch (when applicable): sales of approved therapeutics through specialty channels and partnerships.

Hillstream BioPharma, Inc. (HILS): Ownership Structure

• Patient-centric R&D focus on rare immune, inflammatory, and oncologic indications
• Pipeline emphasis: bispecific antibodies and HER2/HER3-targeting antibody-drug conjugates
• Quality and compliance: GMP standards and regulatory alignment
• Collaborations: strategic partnerships to accelerate preclinical and clinical development

How Hillstream Works & Revenue Model

• Licensing and milestone payments from partners
• Collaborative research agreements and sponsored R&D
• Equity financing, public markets, and potential grant funding for rare disease programs
• Commercial royalties and product sales upon approval and market entry

Ownership and Governance Highlights

• Ownership typically comprises founders, executive insiders, early investors, and public shareholders; governance guided by a board overseeing clinical and corporate strategy.
• Strategic collaborations and licensing deals dilute technical risk while creating future revenue streams and potential value inflection points.
• Capital raising events (equity offerings, convertible instruments) are the primary mechanisms to fund R&D and clinical progression.

Hillstream BioPharma, Inc. (HILS): Mission and Values

• Drug‑delivery platform - Tharimmune's proprietary QUATRAMER platform is engineered to improve uptake and retention of therapeutic agents in the tumor microenvironment, enabling higher local drug concentrations while aiming to limit systemic exposure.
• Bispecific antibodies - Hillstream advances bispecific antibody programs that concurrently target HER2 and HER3, designed to enhance receptor blockade, interfere with heterodimer signaling, and improve antitumor potency in HER2/HER3 driven solid tumors.
• Antibody‑drug conjugates (ADCs) - The company develops ADCs that couple tumor‑directed antibodies to cytotoxic payloads via optimized linkers to maximize selective killing of cancer cells and payload delivery efficiency.
• AI precision medicine - Hillstream employs artificial intelligence platforms to analyze multiomic and clinical datasets to identify predictive biomarkers, refine patient selection, and prioritize indications most likely to respond to targeted agents.
• Clinical‑stage asset expansion - Strategic pursuit of clinical assets (e.g., advancement toward acquiring TH104) is intended to move the company into later development stages, increasing near‑term clinical data potential and de‑risking the pipeline.
• Oral biologics - Research into oral biologic formulations targets improved patient compliance and quality of life by developing less invasive dosing options for biologic therapies traditionally administered by injection or infusion.

• Value creation through staged R&D: advancing internal programs (platform, bispecifics, ADCs, oral biologics) to preclinical, IND, and clinical milestones to increase asset value.
• Asset acquisitions and licensing: acquiring clinical‑stage assets (e.g., TH104) to accelerate the timeline to clinical readouts and create near‑term partnering or out‑licensing opportunities.
• Out‑licensing and partnerships: partnering with larger biopharma for late‑stage development, commercialization, or regional rights to generate upfront payments, milestone payments, and royalties.
• Collaborative development and research agreements: leveraging AI biomarker platforms and QUATRAMER to form fee‑for‑service or co‑development collaborations with academic centers or industry partners.

• Biomarker‑driven trials - Use AI to stratify patients most likely to benefit (companion diagnostic development and enriched clinical cohorts).
• Combination strategies - Pair QUATRAMER‑delivered agents, bispecifics, or ADCs with SOC agents or immune modulators where preclinical synergy is demonstrated.
• Regulatory acceleration - Targeting IND filings and investigator‑initiated studies to generate early human data; clinical‑stage acquisitions intended to shorten time to pivotal studies.

• Scientific and clinical risk - Platform and novel modalities require validation in humans; success depends on translation of preclinical efficacy to clinical benefit.
• Financing and dilution - As a development‑stage company, funding needs for R&D and acquisitions may require capital raises, partnerships, or milestone‑based financing.
• Regulatory and commercial execution - Securing favorable clinical readouts, regulatory approvals, and downstream commercialization or licensing deals are essential to realize shareholder value.
• Near‑term catalysts - Successful acquisition and clinical advancement of assets such as TH104 and initial IND filings for lead programs.

Hillstream BioPharma, Inc. (HILS) How It Works

• Core activities: discovery, IND-enabling studies, clinical trials (Phase 1-3), regulatory submissions, and commercialization planning.
• Pipeline focus: therapies targeting unmet needs in rare diseases and oncology, with strategic prioritization of assets showing favorable safety and efficacy profiles.
• Business model drivers: intellectual property, clinical evidence, strategic collaborations, and market access strategies for specialty indications.

• Licensing and collaboration fees: Hillstream may generate upfront fees, milestone payments, and royalties from licensing agreements with partners (e.g., the September 2024 licensing agreement with Intract Pharma).
• Equity capital raises: the company raised $15.0 million in gross proceeds from its initial public offering in January 2022 to fund R&D and operations.
• Product sales: if/when therapies gain regulatory approval, revenue would come from direct product sales in target markets (rare disease and oncology segments often command premium pricing).
• Grants and public funding: potential non-dilutive support via government grants, orphan drug incentives, and research programs.
• Strategic partnerships: funding, cost-sharing, and co-development arrangements with larger biopharma firms or specialty companies.

• Value inflection points: positive Phase results, IND/CTA approvals, regulatory submissions, and executed partnerships-each can trigger milestone revenue or equity-based capital raises.
• Revenue timing: licensing and milestones can provide near- to mid-term non-dilutive inflows, while product sales depend on successful late-stage trials and commercialization timelines (often several years for biotech programs).
• Cost structure: R&D (clinical trials, manufacturing, regulatory), SG&A for commercialization planning, and milestone payments to co-development partners.

Hillstream BioPharma, Inc. (HILS): How It Makes Money

• Core revenue pathways:
  • Partnering and licensing deals for clinical-stage assets (upfront payments, milestones, royalties).
  • Co-development and joint-venture arrangements to share clinical and commercialization costs.
  • Out-licensing of non-core programs or territories.
  • Potential net product sales upon regulatory approval and market launch.
• Near-term cash inflows are primarily expected from milestone-triggered payments tied to clinical development and strategic transactions (e.g., the planned Intract Pharma merger).

• Therapeutic focus:
  • Bispecific antibodies and antibody-drug conjugates (ADCs) targeting HER2/HER3-positive solid tumors - a segment where HER2-driven disease represents roughly 15-20% of breast cancer cases and a meaningful subset across gastric and other solid tumors.
  • Oral biologics and next-generation delivery enabled by the planned merger with Intract Pharma, which could open new administration routes and expand addressable markets.
• Competitive landscape and trends:
  • Cancer immunotherapy and targeted biologics have seen accelerating approvals; ADCs and bispecifics have become core growth drivers within oncology pipelines.
  • Market dynamics favor companies that can demonstrate superior efficacy/safety or novel delivery modes that improve adherence and reduce healthcare costs.
• Regulatory and quality posture:
  • Commitment to regulatory compliance and manufacturing quality is central to reducing development risk and enabling commercial readiness.

• Capital needs: Small-cap biotechs typically fund operations through equity raises, partner financing, or milestone-linked receipts; Hillstream's near-term liquidity and burn rate will influence timing of clinical readouts and partnering strategies.
• Value inflection points:
  • Clinical proof-of-concept data for Tharimmune programs (early efficacy/safety signals) can materially increase valuation and licensing interest.
  • Progress toward oral biologic capability post-merger could unlock new commercial channels and pricing premiums if bioavailability and manufacturability are demonstrated.
• Risk factors: Clinical development risk, regulatory uncertainty, competition from established oncology biologics, and capital-market volatility.